JP2003535895A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535895A5
JP2003535895A5 JP2002503289A JP2002503289A JP2003535895A5 JP 2003535895 A5 JP2003535895 A5 JP 2003535895A5 JP 2002503289 A JP2002503289 A JP 2002503289A JP 2002503289 A JP2002503289 A JP 2002503289A JP 2003535895 A5 JP2003535895 A5 JP 2003535895A5
Authority
JP
Japan
Prior art keywords
composition according
composition
weight
filler
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002503289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/006983 external-priority patent/WO2001097805A2/en
Publication of JP2003535895A publication Critical patent/JP2003535895A/ja
Publication of JP2003535895A5 publication Critical patent/JP2003535895A5/ja
Withdrawn legal-status Critical Current

Links

JP2002503289A 2000-06-22 2001-06-20 固体バルサルタン医薬組成物 Withdrawn JP2003535895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
US09/599,687 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007003546A Division JP2007091758A (ja) 2000-06-22 2007-01-11 固体バルサルタン医薬組成物

Publications (2)

Publication Number Publication Date
JP2003535895A JP2003535895A (ja) 2003-12-02
JP2003535895A5 true JP2003535895A5 (cg-RX-API-DMAC7.html) 2007-03-15

Family

ID=24400655

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002503289A Withdrawn JP2003535895A (ja) 2000-06-22 2001-06-20 固体バルサルタン医薬組成物
JP2007003546A Withdrawn JP2007091758A (ja) 2000-06-22 2007-01-11 固体バルサルタン医薬組成物
JP2012172246A Pending JP2012211200A (ja) 2000-06-22 2012-08-02 固体バルサルタン医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007003546A Withdrawn JP2007091758A (ja) 2000-06-22 2007-01-11 固体バルサルタン医薬組成物
JP2012172246A Pending JP2012211200A (ja) 2000-06-22 2012-08-02 固体バルサルタン医薬組成物

Country Status (21)

Country Link
EP (2) EP2072049A3 (cg-RX-API-DMAC7.html)
JP (3) JP2003535895A (cg-RX-API-DMAC7.html)
KR (2) KR100659644B1 (cg-RX-API-DMAC7.html)
CN (2) CN1221256C (cg-RX-API-DMAC7.html)
AU (2) AU8576801A (cg-RX-API-DMAC7.html)
BR (1) BR0111868A (cg-RX-API-DMAC7.html)
CA (1) CA2411882C (cg-RX-API-DMAC7.html)
CZ (1) CZ20024180A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP024389A (cg-RX-API-DMAC7.html)
HK (1) HK1052868A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0301390A3 (cg-RX-API-DMAC7.html)
IL (2) IL153428A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02012683A (cg-RX-API-DMAC7.html)
NO (1) NO20026123L (cg-RX-API-DMAC7.html)
NZ (2) NZ522953A (cg-RX-API-DMAC7.html)
PL (1) PL358290A1 (cg-RX-API-DMAC7.html)
RU (1) RU2333757C2 (cg-RX-API-DMAC7.html)
SG (1) SG162605A1 (cg-RX-API-DMAC7.html)
SK (1) SK18062002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001097805A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200210359B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143233A0 (en) * 1998-12-23 2002-04-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
PL2033629T3 (pl) 2004-12-24 2013-04-30 Krka Stała kompozycja farmaceutyczna zawierająca walsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
WO2009048848A1 (en) 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
BR9609066A (pt) * 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
MY119312A (en) * 1995-10-06 2005-05-31 Novartis Ag At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
ES2189940T3 (es) * 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
IL124935A (en) * 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dispersible antifungal compositions comprising itraconazole with improved bioavailability
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IL143233A0 (en) * 1998-12-23 2002-04-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds

Similar Documents

Publication Publication Date Title
JP2003535895A5 (cg-RX-API-DMAC7.html)
JP2007091758A5 (cg-RX-API-DMAC7.html)
JP4108980B2 (ja) 持続放出ラノラジン製剤
EP1441713B2 (en) Modified release tamsulosin tablets
ES2465478T3 (es) Composiciones farmacéuticas que comprenden brivaracetam
JP2015506377A5 (cg-RX-API-DMAC7.html)
WO2009034541A9 (en) Controlled release pharmaceutical dosage forms of trimetazidine
JP2006096757A (ja) 持続放出型ラノラジン製剤
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
AU2002345024B2 (en) Tablet comprising cetirizine and pseudoephedrine
RU2003100507A (ru) Фармацевтические композиции
JP2004518734A (ja) カルベジロールの新規処方
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
US7014867B2 (en) Tablet comprising cetirizine and pseudoephedrine
EP1100472B1 (en) Pharmaceutical compositions comprising ibuprofen and domperidone
US20160008375A1 (en) Pharmaceutical formulations comprising quetiapine and escitalopram
US7959948B2 (en) Pharmaceutical composition of quetiapine fumarate
WO2005011666A1 (en) Stable sustained release oral dosage form of gabapentin
AU756338B2 (en) Stabile compositions comprising levosimendan and alginic acid
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine
EP2231124A1 (en) Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
GR1010345B (el) Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2025108313A1 (zh) 包含egfr抑制剂的药物组合物
EP2846778B1 (en) Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate